Cargando…

Lipoproteins modulate growth and P-glycoprotein expression in drug-resistant HER2-overexpressed breast cancer cells

BACKGROUND: Drug resistance remains as a challenge in the treatment of HER2-overexpressed breast cancer. Emerging evidence from clinical studies show relation of oxidized low density lipoprotein (LDL) and very low density lipoprotein (VLDL) level with drug resistance. However, the underlying molecul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siti, Z.S., Seoparjoo, A.M.I., Shahrul, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488741/ https://www.ncbi.nlm.nih.gov/pubmed/31183434 http://dx.doi.org/10.1016/j.heliyon.2019.e01573

Ejemplares similares

Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer
por: Yoon, Sungpil, et al.
Publicado: (2021)

Selective modulation of P-glycoprotein-mediated drug resistance
por: Bebawy, M, et al.
Publicado: (2001)

Flavonoids modulate multidrug resistance through wnt signaling in P-glycoprotein overexpressing cell lines
por: Mohana, S., et al.
Publicado: (2018)

Overexpression of P‐glycoprotein and resistance to Imatinib in chronic myeloid leukemia patients
por: Ammar, Mariam, et al.
Publicado: (2020)

Retraction Note: Flavonoids modulate multidrug resistance through wnt signaling in P-glycoprotein overexpressing cell lines
por: Mohana, S., et al.
Publicado: (2021)

Study Models of Drug–Drug Interactions Involving P-Glycoprotein: The Potential Benefit of P-Glycoprotein Modulation at the Kidney and Intestinal Levels
por: Veiga-Matos, Jéssica, et al.
Publicado: (2023)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
por: Fiszman, Gabriel L., et al.
Publicado: (2011)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein.
por: Draper, M. P., et al.
Publicado: (1997)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
por: Dent, S., et al.
Publicado: (2009)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells
por: Peng, Xing-Xiang, et al.
Publicado: (2012)

Human Domain Antibodies to Conserved Epitopes on HER2 Potently Inhibit Growth of HER2-Overexpressing Human Breast Cancer Cells In Vitro
por: Wang, Hongqian, et al.
Publicado: (2019)

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
por: Bartsch, R, et al.
Publicado: (2012)

Pluronic P85 decreases the delivery of phenytoin to the brain in drug-resistant rats with P-glycoprotein overexpressed chronic mesial temporal lobe epilepsy
por: Fang, Ziyan, et al.
Publicado: (2023)

P glycoprotein (P-gp) and drug resistance--time for reappraisal?
por: Kaye, S. B.
Publicado: (1993)

Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers
por: Wu, Yanyuan, et al.
Publicado: (2020)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
por: Xing, Fei, et al.
Publicado: (2023)

P(0) Glycoprotein Overexpression Causes Congenital Hypomyelination of Peripheral Nerves
por: Wrabetz, Lawrence, et al.
Publicado: (2000)

P-Glycoprotein and Drug Resistance in Systemic Autoimmune Diseases
por: Picchianti-Diamanti, Andrea, et al.
Publicado: (2014)

Delphinidin Inhibits HER2 and Erk1/2 Signaling and Suppresses Growth of HER2-Overexpressing and Triple Negative Breast Cancer Cell Lines
por: Ozbay, Tuba, et al.
Publicado: (2011)

Response of MCF-7 Breast Cancer Cells Overexpressed with P-Glycoprotein to Apoptotic Induction after Photodynamic Therapy
por: Aniogo, Eric Chekwube, et al.
Publicado: (2021)

Ganoderma tsugae Extract Inhibits Growth of HER2-Overexpressing Cancer Cells via Modulation of HER2/PI3K/Akt Signaling Pathway
por: Kuo, Han-Peng, et al.
Publicado: (2013)

Optical imaging of metabolism in HER2 overexpressing breast cancer cells
por: Walsh, Alex, et al.
Publicado: (2011)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer
por: dos Santos, Giovana Tavares, et al.
Publicado: (2017)

Lipoproteins as Markers for Monitoring Cancer Progression
por: Maran, Logeswaran, et al.
Publicado: (2021)

Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer
por: Kanematsu, Masako, et al.
Publicado: (2015)

Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance.
por: Sakata, K., et al.
Publicado: (1991)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells
por: Ravacci, Graziela Rosa, et al.
Publicado: (2015)

Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells.
por: Versantvoort, C. H., et al.
Publicado: (1993)

Characterization of P-Glycoprotein Inhibitors for Evaluating the Effect of P-Glycoprotein on the Intestinal Absorption of Drugs
por: Kono, Yusuke, et al.
Publicado: (2021)

mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancer
por: Wada, Ryuichi, et al.
Publicado: (2016)

Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade
por: Batalha, Sofia, et al.
Publicado: (2023)

P-glycoprotein transporter in drug development
por: Prachayasittikul, Veda, et al.
Publicado: (2016)

A tumour-associated cell-surface glycoprotein accompanying p53 overexpression and higher growth potential for gastric cancer.
por: Maehara, Y., et al.
Publicado: (1995)

Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
por: Koyama, Kumiko, et al.
Publicado: (2022)

Inhibition of cell growth by BrMC through inactivation of Akt in HER-2/neu-overexpressing breast cancer cells
por: CAO, XIAO-ZHENG, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3s93sgimg6jm6hueukreis17j4